What does Ac-SDKP do? Benefits and evidence
An experimental repair peptide with old human studies, but no proven healing dose.
Also called: AcSDKP, Goralatide, Seraspenide, N-acetyl-seryl-aspartyl-lysyl-proline, Thymosin beta-4 fragment 1–4, TB4-Frag.
Healing and repair peptides · Endogenous tetrapeptide; thymosin beta-4 N-terminal fragment.
Ac-SDKP is a four-part peptide made naturally from thymosin beta-4. Early human studies tested blood-cell protection during chemotherapy and measured how fast it clears. The later cancer trial found no clear protection. Scar reduction and tissue repair remain animal or cell findings. Long-term safety is unknown, with blood-cell suppression and cancer-related concerns.
- In animal studies, it reduced kidney and heart scarring, and heart function improved in mice. (animal)
- In lab studies, skin and hair cells grew more, and isolated hair follicles grew longer. (animal)
- An early chemotherapy study reported it protected blood cells, but a later 84-person trial found no clear benefit. (Studied in a trial)
- One forum user reports taking it daily with BPC-157 as part of a repair stack; any benefit was not verified. (Reported by users)
Uses in the sources
- Studied for blood-cell protection during chemotherapy. Early findings were positive, but the later 84-person trial found no clear benefit. (Studied in a trial) (source)
- Used in community repair stacks. Evidence for reducing organ scarring comes from animals and cells, not human repair trials. (Reported by users) (source)
- Discussed for skin and hair. Published findings used cultured human cells, skin explants and isolated follicles, not treated participants. (Reported by users) (source)
Related to Ac-SDKP
- BPC-157: An experimental repair peptide with mostly animal evidence and a few small human reports.
- TB-500: A short piece of thymosin beta-4 with no proven repair benefit in humans.
- GHK-Cu: A copper-binding skin peptide with small topical studies and untested systemic injections.
- AHK-Cu: A copper peptide used in scalp serums, with laboratory findings and weak patent-only human data.
- Thymosin beta-4: A peptide studied for eye conditions and skin wounds; tendon-repair injections lack controlled human evidence.
- ARA-290: Experimental peptide studied for small-fiber nerve damage, with uncertain pain relief and safety.
Sources
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- Concerns regarding the public health risks associated with unapproved peptide products, Therapeutic Goods Administration and Chief Medical Officer · Therapeutic Goods Administration · 2026
- July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee - 07/23/2026, FDA · FDA · 2026
- MHRA Products | Home, MHRA · MHRA · 2026
- TGA warning on the risks of importing unapproved peptide products, Therapeutic Goods Administration · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2025
- Anaphylaxis: MedlinePlus Medical Encyclopedia, MedlinePlus · MedlinePlus
- Cellulitis: MedlinePlus Medical Encyclopedia, MedlinePlus
- GORALATIDE, NIH NCATS
- GORALATIDE, FDA
- Recognizing medical emergencies: MedlinePlus Medical Encyclopedia, MedlinePlus
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.